ALEXION PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
ALEXION PHARMACEUTICALS INC. - More news...
ALEXION PHARMACEUTICALS INC. - More news...
- BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseases
- JCR Pharmaceuticals Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain CargoⓇ for Neurodegenerative Disease
- Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023
- Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics
- ULTOMIRIS® (ravulizumab-cwvz) showed zero relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) with median treatment duration of 73 weeks
- Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022
- Danicopan (ALXN2040) Add-On to ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) Met Primary Endpoint in ALPHA Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experience Clinically Significant Extravascular Hemolysis
- ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilization From Tissues, Potentially Closing Treatment Gaps for Wilson Disease Community
- Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)
- Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021
- Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021
- Alexion Announces Upcoming Data Presentations at the 26th European Hematology Association Virtual Congress
- Alexion Reports First Quarter 2021 Results
- UPDATED Alexion to Report First Quarter 2021 Results on Friday, April 30, 2021
- Alexion to Report First Quarter 2021 Results on Monday, May 3, 2021
- Thinking about buying stock in Iovance Biotherapeutics, Agile Therapeutics, Wipro, TG Therapeutics, or Alexion Pharmaceuticals?
- Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology
- Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals
- Alexion Reports Fourth Quarter and Full Year 2020 Results
- Alexion to Report Fourth Quarter and Full Year 2020 Results on Thursday, February 4, 2021
- ALEXION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alexion Pharmaceuticals, Inc. - ALXN
- Alexion Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19
- Alexion Highlights Commercial, Clinical and Financial Progress at the 39th Annual J.P. Morgan Healthcare Conference
- Alexion to Present at the 39th Annual J.P. Morgan Healthcare Conference
- SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Alexion Pharmaceuticals, Inc. - ALXN
- ALEXION INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alexion Pharmaceuticals, Inc. - ALXN
- SHAREHOLDER ALERT: WeissLaw LLP Investigates Alexion Pharmaceuticals, Inc.
- Thinking about buying stock in Pfizer, Moderna, Arvinas, Veru, or Alexion Pharmaceuticals?
- (ALXN): Johnson Fistel Investigates Proposed Sale of Alexion Pharmaceuticals; Are Shareholders Getting a Fair Deal?
